As a commercial-stage precision oncology company, Aadi has received FDA approval and commercialized FYARRO for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). Aadi's initial focus is the treatment of advanced malignant PEComa, an ultra-rare cancer, where it deployed its nab-particle technology to address unmet therapeutic needs in a highly specialized oncology segment.
Cyborg Score Rationale
Aadi achieved FDA approval for FYARRO and commercial launch, demonstrating clinical and regulatory success in a precision oncology play. However, as a recently acquired company (March 2025) with historical net losses and limited revenue, its independent financial trajectory remains constrained. Integration under KAKEN's ownership provides capital and operational stability.
Top Insights
FYARRO received FDA approval in November 2021 and launched in the United States in February 2022
As of December 31, 2023, the company had an accumulated deficit of $269.0 million and a net loss of $65.8 million for the year
Acquisition by KAKEN Pharmaceutical (March 2025) marks a strategic transition from independent public company to private subsidiary
Nab-particle platform enables improved drug delivery and intratumoral concentration targeting rare cancers with defined genetic alterations
Named Competitors
Everolimus (Afinitor) — mTOR inhibitor for advanced cancers and rare diseases
Temsirolimus — mTOR inhibitor for renal cell carcinoma and other cancers
Recent Developments
(November 2021) FYARRO (nab-sirolimus) approved by FDA for advanced malignant PEComa
(February 2022) FYARRO commercial launch in the United States
(March 2025) Acquired by KAKEN Pharmaceutical Co., Ltd. (Japan)
Open the full interactive Aadi Bioscience, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.